Steris Corp. (STE)

$225.45

-3.26

(-1.43%)

Market is closed - opens 7 PM, 19 Jul 2024

Performance

  • $223.74
    $229.82
    $225.45
    downward going graph

    0.76%

    Downside

    Day's Volatility :2.65%

    Upside

    1.9%

    downward going graph
  • $194.58
    $251.62
    $225.45
    downward going graph

    13.69%

    Downside

    52 Weeks Volatility :22.67%

    Upside

    10.4%

    downward going graph

Returns

PeriodSteris Corp.Sector (Health Care)S&P500
3 Months
13.89%
8.7%
11.5%
6 Months
3.74%
8.0%
16.9%
1 Year
0.78%
14.0%
22.7%
3 Years
11.95%
17.0%
29.1%

Highlights

Market Capitalization
22.5B
Book Value
$63.73
Dividend Share
2.03
Dividend Yield
0.91%
Earnings Per Share (EPS)
5.55
PE Ratio
41.02
PEG Ratio
6.88
Wall Street Target Price
243.49
Profit Margin
7.36%
Operating Margin TTM
18.83%
Return On Assets TTM
5.18%
Return On Equity TTM
8.92%
Revenue TTM
5.1B
Revenue Per Share TTM
52.02
Quarterly Revenue Growth YOY
2.5%
Gross Profit TTM
2.2B
EBITDA
1.4B
Diluted Eps TTM
5.55
Quarterly Earnings Growth YOY
0.14
EPS Estimate Current Year
8.6
EPS Estimate Next Year
9.33
EPS Estimate Current Quarter
2.35
EPS Estimate Next Quarter
2.03

Analyst Recommendation

Buy
    58%Buy
    41%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Steris Corp.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
5
5
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 8.0%

Current $225.45
Target $243.49

Company Financials

FY19Y/Y Change
Revenue
2.8B
↑ 6.19%
Net Income
304.1M
↑ 4.52%
Net Profit Margin
10.93%
↓ 0.17%
FY20Y/Y Change
Revenue
3.0B
↑ 8.94%
Net Income
407.7M
↑ 34.08%
Net Profit Margin
13.45%
↑ 2.52%
FY21Y/Y Change
Revenue
3.1B
↑ 2.53%
Net Income
397.4M
↓ 2.52%
Net Profit Margin
12.79%
↓ 0.66%
FY22Y/Y Change
Revenue
4.6B
↑ 47.55%
Net Income
243.9M
↓ 38.63%
Net Profit Margin
5.32%
↓ 7.47%
FY23Y/Y Change
Revenue
5.0B
↑ 8.13%
Net Income
107.0M
↓ 56.12%
Net Profit Margin
2.16%
↓ 3.16%
FY24Y/Y Change
Revenue
5.1B
↑ 3.65%
Net Income
378.2M
↑ 253.4%
Net Profit Margin
7.36%
↑ 5.2%
Q4 FY22Q/Q Change
Revenue
1.2B
↑ 1.29%
Net Income
123.3M
↓ 139.12%
Net Profit Margin
10.14%
↑ 36.4%
Q1 FY23Q/Q Change
Revenue
1.4B
↑ 13.89%
Net Income
187.2M
↑ 51.81%
Net Profit Margin
13.52%
↑ 3.38%
Q2 FY23Q/Q Change
Revenue
1.3B
↓ 7.24%
Net Income
123.6M
↓ 34.01%
Net Profit Margin
9.62%
↓ 3.9%
Q3 FY23Q/Q Change
Revenue
1.3B
↑ 4.5%
Net Income
115.3M
↓ 6.67%
Net Profit Margin
8.59%
↓ 1.03%
Q4 FY23Q/Q Change
Revenue
1.4B
↑ 3.97%
Net Income
140.7M
↑ 22.05%
Net Profit Margin
10.08%
↑ 1.49%
Q1 FY24Q/Q Change
Revenue
1.4B
↑ 1.7%
Net Income
-1.4M
↓ 100.98%
Net Profit Margin
-0.1%
↓ 10.18%
FY19Y/Y Change
Total Assets
5.1B
↓ 2.45%
Total Liabilities
1.9B
↓ 4.83%
FY20Y/Y Change
Total Assets
5.4B
↑ 6.95%
Total Liabilities
2.0B
↑ 6.97%
FY21Y/Y Change
Total Assets
6.6B
↑ 21.18%
Total Liabilities
2.7B
↑ 32.9%
FY22Y/Y Change
Total Assets
11.5B
↑ 74.2%
Total Liabilities
4.9B
↑ 82.93%
FY23Y/Y Change
Total Assets
10.8B
↓ 5.51%
Total Liabilities
4.7B
↓ 3.53%
FY24Y/Y Change
Total Assets
11.1B
↑ 2.23%
Total Liabilities
4.7B
↑ 0.29%
Q4 FY22Q/Q Change
Total Assets
10.8B
↑ 2.96%
Total Liabilities
4.8B
↑ 1.61%
Q1 FY23Q/Q Change
Total Assets
10.8B
↑ 0.2%
Total Liabilities
4.7B
↓ 0.35%
Q2 FY23Q/Q Change
Total Assets
10.8B
↓ 0.35%
Total Liabilities
4.6B
↓ 2.72%
Q3 FY23Q/Q Change
Total Assets
11.3B
↑ 4.6%
Total Liabilities
5.1B
↑ 10.54%
Q4 FY23Q/Q Change
Total Assets
11.4B
↑ 1.37%
Total Liabilities
5.0B
↓ 1.66%
Q1 FY24Q/Q Change
Total Assets
11.1B
↓ 3.25%
Total Liabilities
4.7B
↓ 5.17%
FY19Y/Y Change
Operating Cash Flow
539.5M
↑ 17.89%
Investing Cash Flow
-213.2M
↑ 4.61%
Financing Cash Flow
-294.8M
↓ 17.24%
FY20Y/Y Change
Operating Cash Flow
590.6M
↑ 9.46%
Investing Cash Flow
-319.7M
↑ 49.95%
Financing Cash Flow
-163.1M
↓ 44.66%
FY21Y/Y Change
Operating Cash Flow
689.6M
↑ 16.78%
Investing Cash Flow
-1.2B
↑ 260.97%
Financing Cash Flow
345.6M
↓ 311.85%
FY22Y/Y Change
Operating Cash Flow
684.8M
↓ 0.7%
Investing Cash Flow
-666.6M
↓ 42.25%
Financing Cash Flow
115.8M
↓ 66.49%
FY23Y/Y Change
Operating Cash Flow
756.9M
↑ 10.53%
Investing Cash Flow
-383.3M
↓ 42.49%
Financing Cash Flow
-498.7M
↓ 530.56%
Q4 FY22Q/Q Change
Operating Cash Flow
205.6M
↑ 98.01%
Investing Cash Flow
-98.4M
↑ 0.5%
Financing Cash Flow
-120.4M
↑ 167.89%
Q1 FY23Q/Q Change
Operating Cash Flow
215.8M
↑ 4.97%
Investing Cash Flow
-77.6M
↓ 21.17%
Financing Cash Flow
-191.9M
↑ 59.41%
Q2 FY23Q/Q Change
Operating Cash Flow
281.1M
↑ 30.27%
Investing Cash Flow
-66.6M
↓ 14.16%
Financing Cash Flow
-213.6M
↑ 11.3%
Q3 FY23Q/Q Change
Operating Cash Flow
146.1M
↓ 48.03%
Investing Cash Flow
-672.8M
↑ 910.32%
Financing Cash Flow
470.2M
↓ 320.1%

Technicals Summary

Sell

Neutral

Buy

Steris Corp. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Steris Corp.
Steris Corp.
5.64%
3.74%
0.78%
11.95%
54.67%
Stryker Corporation
Stryker Corporation
-4.02%
6.33%
12.81%
34.45%
59.01%
Boston Scientific Corp.
Boston Scientific Corp.
1.44%
26.8%
46.58%
87.75%
81.54%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-1.37%
17.29%
-5.09%
-15.16%
35.66%
Abbott Laboratories
Abbott Laboratories
0.66%
-8.19%
-2.12%
-11.88%
19.28%
Medtronic Plc
Medtronic Plc
1.89%
-5.83%
-6.17%
-33.8%
-19.81%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Steris Corp.
Steris Corp.
41.02
41.02
6.88
8.6
0.09
0.05
0.01
63.73
Stryker Corporation
Stryker Corporation
38.02
38.02
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
65.66
65.66
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.63
37.63
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
31.9
31.9
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.3
28.3
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Steris Corp.
Steris Corp.
Buy
$22.5B
54.67%
41.02
7.36%
Stryker Corporation
Stryker Corporation
Buy
$127.0B
59.01%
38.02
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.9B
81.54%
65.66
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.9B
35.66%
37.63
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$178.7B
19.28%
31.9
13.96%
Medtronic Plc
Medtronic Plc
Buy
$100.1B
-19.81%
28.3
11.36%

Insights on Steris Corp.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 1.28B → 1.41B (in $), with an average increase of 3.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 140.74M → -1.37M (in $), with an average decrease of 101.0% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 46.6% return, outperforming this stock by 45.8%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 83.9% return, outperforming this stock by 73.8%

Institutional Holdings

  • Vanguard Group Inc

    11.98%
  • BlackRock Inc

    9.94%
  • Massachusetts Financial Services Company

    5.73%
  • WCM Investment Management

    4.79%
  • State Street Corporation

    4.17%
  • Morgan Stanley - Brokerage Accounts

    3.93%

Corporate Announcements

  • Steris Corp. Dividends March,2024

    In the quarter ending March,2024. Steris Corp. has declared dividend of $0.52

    Read More

Company Information

steris is a leading provider of infection prevention and procedural surgical products and services, focused primarily on healthcare, pharmaceutical, research and medical device customers. our mission is to provide a healthier today and a safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. while the corporation was founded as innovative medical technologies in 1985 and renamed steris in 1987, our history dates back to 1894 with the founding of american sterilizer company, a long-time, global leading innovator of sterilization products. today, through a series of strategic acquisitions and continual innovation of new products, steris holds one of the broadest portfolios of products in the industry. it stands at the forefront of efforts to prevent infection and contamination in healthcare, pharmaceutical and medical device environments.

Organization
Steris Corp.
Employees
18000
CEO
Mr. Daniel A. Carestio
Industry
Health Technology

FAQs